After announcing the state would initiate coverage of GLP-1s to combat obesity in September 2022 as part of their state employee health plan, the state reversed course and in January 2025 announced it was opting to end that coverage beginning July 1, 2025
Theyve transformed diabetes care and opened new possibilities for long-term weight management, but they can be expensive without insurance
One medication that works this way is Tirzepatide, which targets both hormone pathways
Documentation for building strong cases encompasses the following elements: Prescription history showing Ozempic dosage, duration, and prescribing indication (diabetes versus weight loss) Emergency department records detailing acute symptom presentation and treatment Hospitalization records demonstrating severity through admission duration, IV hydration, nutritional support Diagnostic test results including gastric emptying studies, upper endoscopy ruling out obstruction, CT scans Gastroenterologist consultation notes confirming gastroparesis diagnosis Ongoing treatment records showing persistent symptoms and quality of life impacts Documentation of work absences, disability claims, or lifestyle modifications necessitated by symptoms Certain factors may disqualify or weaken potential claims, making early case evaluation
Bonaquist has no affiliation with any of the drug companies mentioned in this article and receives no compensation for their use
GLP-1 medications are formulated strictly for subcutaneous (under-the-skin fat layer) injection
